Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC

Johns Hopkins University1 个研究点分布在 1 个国家目标入组 28 人2022年5月23日

干预措施Oral Placebo Oral Delta-8-THC Cannabis Oral Delta-9-THC Cannabis Vaporized Placebo Vaporized Delta-8-THC Cannabis Vaporized Delta-9-THC Cannabis

概览

阶段: 1 期
干预措施: Oral Placebo
疾病 / 适应症: Behavioral Pharmacology of Cannabis
发起方: Johns Hopkins University
入组人数: 28
试验地点: 1
主要终点: Self-reported Drug Effect ratings on the Drug Effect Questionnaire (DEQ)
状态: 已完成
最后更新: 2个月前

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

The current study will investigate the subjective, physiological, and cognitive performance effects of inhaled and orally ingested Delta-8 tetrahydrocannabinol (THC) in comparison to both placebo and Delta-9 THC. The purpose of this study is to assess the effects of Delta-8 THC as compared to placebo and Delta-9 THC. Oral fluid, urine, blood, and hair specimens will be collected from participants.

详细描述

The current study will investigate the subjective, physiological, and cognitive performance effects of inhaled and orally ingested Delta-8 THC in comparison to both placebo and Delta-9 THC. Delta-8 THC is an cannabinoid that has become widely available for retail sale in the US due to a loophole in the 2018 Farm Bill. Delta-8 THC is an isomer of Delta-9 THC, which is the compound responsible for most of the psychoactive effects associated with cannabis. Prior research, while limited, has indicated that Delta-8 THC is less potent but has comparable pharmacodynamic effects to Delta-9 THC, especially at higher doses. The purpose of this study is to assess the effects of Delta-8 THC as compared to placebo and Delta-9 THC. Oral fluid, urine, blood, and hair specimens will be collected from participants. The investigators will recruit healthy participants between the ages of 18 and 45 who have prior experience using THC but have not used in at least one month. Two sub-studies will be run, with 5 conditions in each study; sub-study 1 will examine the effects of vaporized Delta-8 THC and sub-study 2 will assess the effects of orally ingested Delta-8 THC. Participants can complete both sub-studies but it is not required. There will be a minimum of 5 outpatient drug administration sessions for each participant, with the option to complete 5 more if interested. The investigators will recruit and consent up to 70 participants in order to obtain 20 completers (up to 40 total individuals) for each sub-study.

注册库

clinicaltrials.gov

开始日期

2022年5月23日

结束日期

2024年10月2日

最后更新

2个月前

研究类型

Interventional

研究设计

Crossover

性别

All

研究者

发起方

Johns Hopkins University

责任方

Sponsor

入排标准

入选标准

•Have provided written informed consent
•Be between the ages of 18 and 45
•Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
•Test negative for recent cannabis use in urine at the screening visit and again upon admission for each experimental session
•Test negative for other drugs of abuse, including alcohol at the screening visit and upon arrival for each experimental session
•Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.
•Have a body mass index (BMI) in the range of 19 to 36 kg/m2
•Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
•Report prior experience inhaling cannabis (either via smoking or vaporization).
•Have not donated blood in the prior 30 days.

排除标准

•Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the Screening Visit;
•History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
•Use of an over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
•Use of a prescription medication (with the exception of birth control prescriptions) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce/inhibit CYP3A4 enzymes.
•Use of any hemp, cannabis or cannabinoid product in the past 3 months.
•History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.
•History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
•Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.
•Epilepsy or a history of seizures.
•Individuals who have a recent history of traumatic brain injury diagnosed by CT/MRI and have current sequela from prior brain injury, as determined by the study physician.